• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Visiox Pharma Appoints Industry Leader Ryan S. Bleeks as Chief Executive Officer

Article

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced the appointment of Ryan S. Bleeks as Chief Executive Officer.

Ryan S. Bleeks

Ryan S. Bleeks

Most recently Mr. Bleeks was the Vice President of Sales, Sales Training and Sales Operations at RVL Pharmaceuticals plc, where he was responsible for building the infrastructure, sales force and launch execution of UPNEEQ®, the first product to treat acquired blepharoptosis in adults with an innovative prescription cash pay strategy.

"We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's Founding Investor and Executive Chairman. "His proven leadership in building teams, company infrastructure and executing successful launch strategies in the ophthalmics space will be instrumental as we accelerate our path towards commercialization."


Related Videos
Related Content